Latest Pharmaceuticals News

Page 7 of 63
CSL Limited reported a 7% decline in underlying NPATA to US$1.9 billion for the half-year, weighed down by restructuring costs and impairments, yet maintains full-year guidance and expands its share buy-back program.
Ada Torres
Ada Torres
11 Feb 2026
CSL Limited announces the retirement of CEO Dr Paul McKenzie, with veteran executive Gordon Naylor appointed as interim CEO and Managing Director. The leadership change marks a new chapter for the biotech giant amid ongoing strategic transformation.
Ada Torres
Ada Torres
10 Feb 2026
Island Pharmaceuticals has confirmed the material significance of recent FDA feedback on its Galidesivir development pathway and addressed ASX queries on disclosure timing and capital raising activities.
Ada Torres
Ada Torres
10 Feb 2026
EVE Health Group has officially launched Libbo™, an oral dissolving film for erectile dysfunction, alongside a new digital platform aimed at improving men’s health access and education across Australia.
Ada Torres
Ada Torres
10 Feb 2026
Wellnex Life Limited is exploring acquisition interest and convertible note funding to accelerate Pain Away's expansion and strengthen its financial footing, signaling a pivotal phase in its turnaround journey.
Ada Torres
Ada Torres
9 Feb 2026
Argo Investments has reported a half-year profit of $130.8 million and declared a record fully franked interim dividend of 18.5 cents per share, reflecting strong dividend growth despite a challenging market environment.
Claire Turing
Claire Turing
9 Feb 2026
Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.
Victor Sage
Victor Sage
9 Feb 2026
Neuren Pharmaceuticals has dosed the first patient in its groundbreaking Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome, a rare genetic disorder with no approved therapies. The trial marks a significant step forward for the PMS community and rare disease drug development.
Ada Torres
Ada Torres
6 Feb 2026
Epsilon Healthcare’s subsidiary, Epsilon Pharma, has signed a three-year manufacturing agreement with New Zealand’s Puro to supply medicinal cannabis products to the UK and Europe, marking a significant step in its international expansion.
Ada Torres
Ada Torres
5 Feb 2026
The US Congress has reauthorized the Rare Pediatric Disease Priority Review Voucher program through September 2029, a move that could significantly benefit Neuren Pharmaceuticals as it advances its rare disease drug candidates.
Ada Torres
Ada Torres
5 Feb 2026
Neuren Pharmaceuticals has received detailed feedback from the US FDA on its clinical development plans for NNZ-2591 targeting hypoxic ischemic encephalopathy and Pitt Hopkins syndrome, paving a clearer path forward despite some delays.
Ada Torres
Ada Torres
4 Feb 2026
Island Pharmaceuticals has raised $9 million to advance its antiviral drug Galidesivir through the FDA’s Animal Rule pathway, targeting inclusion in the US Strategic National Stockpile for biodefense viruses.
Victor Sage
Victor Sage
4 Feb 2026